Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Pharmacology
Reference80 articles.
1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97: 8104–8109.
2. American Psychiatric Association, American Psychiatric Association. Task Force on DSM-IV (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, 4th edn. American Psychiatric Association: Washington, DC. xxxvii, p 943.
3. Ashburner J, Friston KJ (2005). Unified segmentation. Neuroimage 26: 839–851.
4. Boileau I, Nakajima S, Payer D (2015). Imaging the D3 dopamine receptor across behavioral and drug addictions: positron emission tomography studies with [(11)C]-(+)-PHNO. Eur Neuropsychopharmacol 25: 1410–1420.
5. Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J et al (2012). Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci 32: 1353–1359.